Re-administration of a combination of chemotherapy plus Gemtuzumab at relapse in CD33+AML patient allows to second remission and is feasible without extra toxicity

被引：4

作者：

Chevallier, Patrice ^{[1
]}

Touzeau, Cyril ^{[1
]}

Ayari, Sameh ^{[1
]}

Guillaume, Thierry ^{[1
]}

Harousseau, Jean-Luc ^{[1
]}

Delaunay, Jacques ^{[1
]}

机构：

[1] CHU Nantes, Serv Hematol Clin, Dept Hematol, F-44093 Nantes 01, France

来源：

LEUKEMIA RESEARCH | 2008年 / 32卷 / 08期

关键词：

gemtuzumab; AML; CD33; toxicity;

D O I：

10.1016/j.leukres.2007.09.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

As combination of chemotherapy and Gemtuzumab may become a common induction regimen for CD33+ AML patients, there is no report assessing the safety and toxicity of a re-treatment at relapse with such combination in a same patient. Here we describe the case of a 69-year-old patient who achieved a second complete remission with this association without additional toxicity. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：1321 / 1322

页数：2

共 8 条

[1] The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial. [J].

Burnett, Alan K. ;

Kell, William J. ;

Goldstone, Anthony H. ;

Milligan, Donald ;

Hunter, Ann ;

Prentice, Archie G. ;

Russell, Nigel H. ;

Gibson, Brenda ;

Wheatley, Keith ;

Hills, Robert K. .

BLOOD, 2006, 108 (11) :8A-8A

[2] Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia [J].

Chevallier, P ;

Roland, V ;

Mahé, B ;

Juge-Morineau, N ;

Dubruille, V ;

Guillaume, T ;

Vigouroux, S ;

Moreau, P ;

Milpied, N ;

Garand, R ;

Avet-Loiseau, H ;

Harousseau, JL .

LEUKEMIA RESEARCH, 2005, 29 (09) :1003-1007

[3] Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence [J].

Larson, RA ;

Sievers, EL ;

Stadtmauer, EA ;

Löwenberg, B ;

Estey, EH ;

Dombret, H ;

Theobald, M ;

Voliotis, D ;

Bennett, JM ;

Richie, M ;

Leopold, LH ;

Berger, MS ;

Sherman, ML ;

Loken, MR ;

van Dongen, JJM ;

Bernstein, ID ;

Appelbaum, FR .

CANCER, 2005, 104 (07) :1442-1452

[4] Antibody-targeted chemotherapy of relapsed AML [J].

Mineur, P ;

Lejeune, C ;

Hennaux, V ;

Eten, C .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (01) :195-196

[5] Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older [J].

Nabhan, C ;

Rundhaugen, LM ;

Riley, MB ;

Rademaker, A ;

Boehlke, L ;

Jati, M ;

Tallman, MS .

LEUKEMIA RESEARCH, 2005, 29 (01) :53-57

[6] Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+primary resistant or relapsed acute myeloid leukemia [J].

Tsimberidou, A ;

Cortes, J ;

Thomas, D ;

Garcia-Manero, G ;

Verstovsek, S ;

Faderl, S ;

Albitar, M ;

Kantarjian, H ;

Estey, E ;

Giles, FJ .

LEUKEMIA RESEARCH, 2003, 27 (10) :893-897

[7] Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes [J].

Tsimberidou, A ;

Estey, E ;

Cortes, J ;

Thomas, D ;

Faderl, S ;

Verstovsek, S ;

Garcia-Manero, G ;

Keating, M ;

Albitar, M ;

O'Brien, S ;

Kantarjian, H ;

Giles, F .

CANCER, 2003, 97 (06) :1481-1487

[8] Gemtuzumab ozogamicin:: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis [J].

Zwaan, CM ;

Reinhardt, D ;

Corbacioglu, S ;

van Wering, ER ;

Bökkerink, JPM ;

Tissing, WJE ;

Samuelsson, U ;

Feingold, J ;

Creutzig, U ;

Kaspers, GJL .

BLOOD, 2003, 101 (10) :3868-3871

← 1 →